Categories

Entrada publicada a:

Thursday December 13th, 2012

Bariatric surgery improves metabolic and inflammatory profile of those morbid obesity patients undergoing surgery

Annals of Surgery publishes a work which shows type 2 diabetes remission rates over 60% in morbid obesity patients undergoing bariatric surgery. Initially this percentage reaches 75% but the disease reappears when weight control and healthy lifestyle are not maintained at the long-term. Metabolic control is improved even when there is not a complete diabetes remission. With Amanda Jimenez as the first author, the work was led by Dr. Josep Vidal, head of the Endocrinology and Nutrition Service at Hospital Clínic and leader of the IDIBAPS team Diabetes: metabolic and molecular networks, and Dr. Antonio M. Lacy, Head of the Gastrointestinal Surgery Service at the Hospital Clínic and member of the IDIBAPS team Gastrointestinal and pancreatic Oncology.

Morbid obesity is associated with a number of metabolic and inflammatory alterations. These changes are the basis of future illnesses that may not have yet clinically appeared at the time of surgery. A study published in Obesity Surgery discusses the effects of bariatric surgery on these alterations, with particular interest in those patients without insulin resistance. The results demonstrate that improvements are sensitive even in patients with better conditions before surgery.

These doctors and researchers, along with their teams, also lead recent works about the protein intake in the diet to be followed by patients after bariatric surgery (Clinical Nutrition) or on the potential for NOTES surgery (Natural Orifice Transluminal Endoscopy Surgery) (Current Gastroenterology Reports), a technique for which the Hospital Clínic de Barcelona is a reference pioneer. Tomorrow December 14th is the National Day Against Obesity, although professionals at the Hospital Clinic of Barcelona and IDIBAPS work all year to combat this growing problem.

Share or bookmark this post

  • Delicious
  • Facebook
  • Twitter
  • email
  • LinkedIn
  • StumbleUpon

    Comments are closed.